In contrast, inhibiting PDE4 increases cAMP levels, leading to a reduction in the expression of key cytokines involved in the pathophysiology of psoriasis, including TNF, IFN-γ, IL-17, and IL-23 [28]. The gene discussed is PDE4A; the disease is psoriasis.